[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN109715626A - 作为fgfr抑制剂的杂环化合物 - Google Patents

作为fgfr抑制剂的杂环化合物 Download PDF

Info

Publication number
CN109715626A
CN109715626A CN201780045675.XA CN201780045675A CN109715626A CN 109715626 A CN109715626 A CN 109715626A CN 201780045675 A CN201780045675 A CN 201780045675A CN 109715626 A CN109715626 A CN 109715626A
Authority
CN
China
Prior art keywords
alkyl
ring group
independently selected
circle heterocyclic
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780045675.XA
Other languages
English (en)
Other versions
CN109715626B (zh
Inventor
孔祥龙
周超
陈向阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Innocare Pharma Tech Co ltd
Original Assignee
Nanjing Innocare Pharma Tech Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Innocare Pharma Tech Co ltd filed Critical Nanjing Innocare Pharma Tech Co ltd
Publication of CN109715626A publication Critical patent/CN109715626A/zh
Application granted granted Critical
Publication of CN109715626B publication Critical patent/CN109715626B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

一类杂环化合物、含有其的药物组合物、以及它们的制备方法和其作为成纤维细胞生长因子受体FGFR抑制剂的用途。该抑制剂为式I所示的杂环化合物，或其药学上可接受的盐、前药、溶剂化合物、多晶型体、异构体、稳定同位素衍生物或含有其的药物组合物。上述化合物可用于治疗或预防由FGFR介导的相关疾病，如癌症。

Description

PCT国内申请，说明书已公开。

Claims (8)

  1. PCT国内申请，权利要求书已公开。
CN201780045675.XA 2016-08-09 2017-07-27 作为fgfr抑制剂的杂环化合物 Active CN109715626B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610647295.0A CN107698593A (zh) 2016-08-09 2016-08-09 作为fgfr抑制剂的杂环化合物
CN2016106472950 2016-08-09
PCT/CN2017/094620 WO2018028438A1 (zh) 2016-08-09 2017-07-27 作为fgfr抑制剂的杂环化合物

Publications (2)

Publication Number Publication Date
CN109715626A true CN109715626A (zh) 2019-05-03
CN109715626B CN109715626B (zh) 2022-04-26

Family

ID=61162708

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610647295.0A Pending CN107698593A (zh) 2016-08-09 2016-08-09 作为fgfr抑制剂的杂环化合物
CN201780045675.XA Active CN109715626B (zh) 2016-08-09 2017-07-27 作为fgfr抑制剂的杂环化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610647295.0A Pending CN107698593A (zh) 2016-08-09 2016-08-09 作为fgfr抑制剂的杂环化合物

Country Status (7)

Country Link
US (1) US10752631B2 (zh)
EP (1) EP3498706A4 (zh)
JP (1) JP6959663B2 (zh)
KR (1) KR20190035870A (zh)
CN (2) CN107698593A (zh)
CA (1) CA3032921A1 (zh)
WO (1) WO2018028438A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115043832A (zh) * 2021-03-08 2022-09-13 药雅科技(上海)有限公司 一种fgfr抑制剂炔代杂环类化合物及其制备方法和用途
CN116096707A (zh) * 2020-06-05 2023-05-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶的抑制剂

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208856A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114127051A (zh) * 2019-05-17 2022-03-01 金耐特生物制药公司 成纤维细胞生长因子受体激酶的抑制剂
EP3976075A4 (en) 2019-05-30 2023-08-16 Gritstone bio, Inc. MODIFIED ADENOVIRUS
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230046313A (ko) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트
CN112480109B (zh) * 2020-11-16 2022-04-01 浙江大学 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途
MX2023008186A (es) * 2021-01-12 2023-07-18 Beijing Innocare Pharma Tech Co Ltd Proceso para preparar (s)-1-(1-acriloilpirrolidin-3-il)-3-((3,5-di metoxifenil)etinil)-5-(metilamino)-1h-pirazol-4-carboxamida.
CN114853739B (zh) * 2021-02-03 2023-09-22 药雅科技(上海)有限公司 一种炔代吡嗪类fgfr抑制剂及其制备方法和用途
WO2024083111A1 (zh) * 2022-10-18 2024-04-25 首药控股(北京)股份有限公司 一种新型杂环化合物
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087395A2 (en) * 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
CN103958512A (zh) * 2012-01-19 2014-07-30 大鹏药品工业株式会社 3,5-双取代炔基苯化合物及其盐
CN104341388A (zh) * 2013-10-16 2015-02-11 上海润诺生物科技有限公司 芳香族酰胺类衍生物、其制备方法及其在医药上的应用
EP3023100A1 (en) * 2013-07-18 2016-05-25 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of fgfr inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015011456A (es) * 2013-03-13 2016-05-31 Boston Biomedical Inc Derivados de 3-(arilo o heteroailo) metilenindolino-2-ona como inhibidores de cinasas de la via de las celulas madres cancerosas para el tratamiento del cancer.
JP6084292B2 (ja) * 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
CN104341425B (zh) * 2013-08-08 2018-11-02 上海医药集团股份有限公司 氘代乙炔衍生物、其药物组合物及应用
PE20170774A1 (es) * 2014-08-19 2017-07-04 Shanghai Haihe Pharmaceutical Co Ltd Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087395A2 (en) * 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
CN103958512A (zh) * 2012-01-19 2014-07-30 大鹏药品工业株式会社 3,5-双取代炔基苯化合物及其盐
EP3023100A1 (en) * 2013-07-18 2016-05-25 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of fgfr inhibitor
CN104341388A (zh) * 2013-10-16 2015-02-11 上海润诺生物科技有限公司 芳香族酰胺类衍生物、其制备方法及其在医药上的应用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096707A (zh) * 2020-06-05 2023-05-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶的抑制剂
CN115043832A (zh) * 2021-03-08 2022-09-13 药雅科技(上海)有限公司 一种fgfr抑制剂炔代杂环类化合物及其制备方法和用途
CN115043832B (zh) * 2021-03-08 2023-08-22 药雅科技(上海)有限公司 一种fgfr抑制剂炔代杂环类化合物及其制备方法和用途

Also Published As

Publication number Publication date
CN107698593A (zh) 2018-02-16
US10752631B2 (en) 2020-08-25
CA3032921A1 (en) 2018-02-15
WO2018028438A1 (zh) 2018-02-15
EP3498706A1 (en) 2019-06-19
JP2019524883A (ja) 2019-09-05
JP6959663B2 (ja) 2021-11-02
US20190177333A1 (en) 2019-06-13
EP3498706A4 (en) 2020-02-26
CN109715626B (zh) 2022-04-26
KR20190035870A (ko) 2019-04-03

Similar Documents

Publication Publication Date Title
CN109715626A (zh) 作为fgfr抑制剂的杂环化合物
CN105524048B (zh) 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用
JP6919922B2 (ja) Ｆｇｆｒ４阻害剤、その製造方法と薬学的な応用
KR102386428B1 (ko) Fgfr 억제제로서 사용되는 헤테로시클릭 화합물
CN107840842A (zh) 炔代杂环化合物、其制备方法及其在医药学上的应用
KR20080009200A (ko) 치환된 헤테로사이클 및 이것의 ｃｈｋ1, ｐｄｋ1 및ｐａｋ 억제제로서의 용도
CN103304572A (zh) 一类3-氰基喹啉类化合物及其药用组合物和应用
CN101932584A (zh) 作为pi3k阻滞剂的吡咯并嘧啶衍生物及其用途
CN105315285A (zh) 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途
WO2018228275A1 (zh) 作为mnk抑制剂的杂环化合物
WO2019223766A1 (zh) 一种fgfr抑制剂、其制备方法和在药学上的应用
CN107266421A (zh) 取代的苯并咪唑类衍生物
WO2021197250A1 (zh) 作为转染期间重排激酶抑制剂的新的化合物
CN111836819A (zh) 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用
WO2019024876A1 (zh) 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用
WO2018233526A1 (zh) 一种csf1r抑制剂及其制备方法和应用
JP2006510727A (ja) キナーゼモジュレーター
CN111138459B (zh) Fgfr4抑制剂的光学异构体及其应用
CN101605794A (zh) 氮杂苯并呋喃基化合物及使用方法
CN114853752A (zh) Btk抑制剂吡啶并杂环类化合物的制备及其应用
CN115073468B (zh) 咪唑并吡嗪类btk抑制剂的制备及用途
CN114650991B (zh) 桥环并醛基吡啶衍生物及其应用
CN110272415A (zh) 3,4-二氢吡啶并[4,3-d]嘧啶类衍生物及其制备方法和用途
CN114957242A (zh) 吡啶并杂环类化合物作为激酶抑制剂的制备及其应用
TW202233632A (zh) 噻吩并嘧啶衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002365

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant